Trial Profile
Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Jun 2016
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Cushing syndrome
- Focus Therapeutic Use
- Sponsors Novartis
- 04 Apr 2016 Results of open-label extension phase at month 60 (n=16) presented at The 98th Annual Meeting of the Endocrine Society
- 25 Sep 2015 New trial record